Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at Advanced Spine and Pain Management Following Successful Pilot with Dr. Varinder Dhillon
Milestone Scientific (NYSE: MLSS) announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, following a successful pilot program with Dr. Varinder Dhillon. The implementation takes place at SurgiCore Montvale, one of 12 SurgiCore centers in the NY/NJ metro area, suggesting potential for network expansion.
The company reports increasing adoption of the system following a recent Medicare price assignment. The CompuFlo® Epidural System, powered by Dynamic Pressure Sensing Technology®, provides real-time feedback for accurate needle placement during epidural procedures, reducing complications associated with traditional techniques.
Dr. Dhillon praised the system's precision and reliability in improving patient care and procedural efficiency. Neal Goldman, Chairman and Interim CEO, highlighted the growing traction within the healthcare community, particularly among pain management clinics nationwide following the Medicare price assignment.
Milestone Scientific (NYSE: MLSS) ha annunciato il lancio commerciale del suo CompuFlo® Epidural System presso Advanced Spine and Pain Management, dopo un programma pilota di successo con il Dr. Varinder Dhillon. L'implementazione avviene presso SurgiCore Montvale, uno dei 12 centri SurgiCore nell'area metropolitana NY/NJ, suggerendo un potenziale per l'espansione della rete.
L'azienda riporta un aumento dell'adozione del sistema dopo un recente assegnamento di prezzo da parte di Medicare. Il CompuFlo® Epidural System, alimentato dalla Dynamic Pressure Sensing Technology®, fornisce feedback in tempo reale per una corretta posizione dell'ago durante le procedure epidurali, riducendo le complicazioni associate alle tecniche tradizionali.
Il Dr. Dhillon ha lodato la precisione e l'affidabilità del sistema nel migliorare la cura dei pazienti e l'efficienza procedurale. Neal Goldman, Presidente e CEO ad interim, ha evidenziato la crescente attenzione nella comunità sanitaria, in particolare tra le cliniche per la gestione del dolore a livello nazionale dopo l'assegnamento di prezzo da parte di Medicare.
Milestone Scientific (NYSE: MLSS) anunció el lanzamiento comercial de su CompuFlo® Epidural System en Advanced Spine and Pain Management, tras un exitoso programa piloto con el Dr. Varinder Dhillon. La implementación se lleva a cabo en SurgiCore Montvale, uno de los 12 centros SurgiCore en el área metropolitana de NY/NJ, lo que sugiere un potencial para la expansión de la red.
La compañía informa sobre un aumento en la adopción del sistema tras una reciente asignación de precios de Medicare. El CompuFlo® Epidural System, impulsado por la Dynamic Pressure Sensing Technology®, proporciona retroalimentación en tiempo real para una colocación precisa de la aguja durante los procedimientos epidurales, reduciendo las complicaciones asociadas con las técnicas tradicionales.
El Dr. Dhillon elogió la precisión y confiabilidad del sistema en la mejora de la atención al paciente y la eficiencia de los procedimientos. Neal Goldman, presidente y CEO interino, destacó la creciente tracción dentro de la comunidad de atención médica, particularmente entre las clínicas de manejo del dolor en todo el país tras la asignación de precios de Medicare.
Milestone Scientific (NYSE: MLSS)는 Dr. Varinder Dhillon과 함께 성공적인 파일럿 프로그램을 거쳐 Advanced Spine and Pain Management에서 CompuFlo® Epidural System의 상업적 출범을 발표했습니다. 이 시스템은 NY/NJ 메트로 지역의 12개 SurgiCore 센터 중 하나인 SurgiCore Montvale에서 시행되며, 네트워크 확장의 가능성을 시사합니다.
회사는 최근 Medicare 가격 지정 후 시스템 채택이 증가하고 있다고 보고했습니다. Dynamic Pressure Sensing Technology®로 구동되는 CompuFlo® Epidural System은 경막외 시술 중 정확한 바늘 위치를 위해 실시간 피드백을 제공하여 전통적인 기술과 관련된 합병증을 줄여줍니다.
Dr. Dhillon은 환자 치료 및 시술 효율성을 개선하는 데 있어 시스템의 정확성과 신뢰성을 칭찬했습니다. Neal Goldman, 회장 겸 임시 CEO는 Medicare 가격 지정 이후 국가 전역의 통증 관리 클리닉에서 의료 커뮤니티 내에서의 증가하는 반응을 강조했습니다.
Milestone Scientific (NYSE: MLSS) a annoncé le lancement commercial de son CompuFlo® Epidural System chez Advanced Spine and Pain Management, suite à un programme pilote réussi avec le Dr Varinder Dhillon. L'implémentation a lieu à SurgiCore Montvale, l'un des 12 centres SurgiCore dans la région métropolitaine NY/NJ, ce qui suggère un potentiel d'expansion du réseau.
L'entreprise rapporte une adoption croissante du système suite à une récente attribution de prix par Medicare. Le CompuFlo® Epidural System, propulsé par la Dynamic Pressure Sensing Technology®, fournit des retours en temps réel pour un placement précis de l'aiguille lors des procédures épidurales, réduisant les complications associées aux techniques traditionnelles.
Le Dr Dhillon a loué la précision et la fiabilité du système pour améliorer les soins aux patients et l'efficacité des procédures. Neal Goldman, président et PDG par intérim, a souligné le soutien croissant au sein de la communauté de santé, en particulier parmi les cliniques de gestion de la douleur à l'échelle nationale après l'attribution de prix par Medicare.
Milestone Scientific (NYSE: MLSS) gab die kommerzielle Einführung seines CompuFlo® Epidural Systems bei Advanced Spine and Pain Management bekannt, nachdem ein erfolgreicher Pilotversuch mit Dr. Varinder Dhillon durchgeführt wurde. Die Implementierung findet im SurgiCore Montvale statt, einem der 12 SurgiCore-Zentren im U-Bahnbereich NY/NJ, was auf ein Potenzial zur Netzwerkausweitung hinweist.
Das Unternehmen berichtet über eine zunehmende Akzeptanz des Systems nach einer kürzlichen Preiszuweisung durch Medicare. Das CompuFlo® Epidural System, das auf der Dynamic Pressure Sensing Technology® basiert, bietet Echtzeit-Feedback für eine präzise Nadelplatzierung während epiduraler Verfahren und reduziert die Komplikationen, die mit traditionellen Techniken verbunden sind.
Dr. Dhillon lobte die Präzision und Zuverlässigkeit des Systems zur Verbesserung der Patientenversorgung und der Effizienz der Verfahren. Neal Goldman, Vorsitzender und amtierender CEO, hob das wachsende Interesse innerhalb der Gesundheitsgemeinschaft hervor, insbesondere bei Schmerzmanagementkliniken im ganzen Land nach der Preiszuweisung durch Medicare.
- Commercial rollout in a major pain management clinic following successful pilot
- Potential expansion opportunity across 12 SurgiCore centers in NY/NJ area
- Increasing adoption following Medicare price assignment
- Technology reduces complications risk compared to traditional techniques
- None.
Insights
The commercial deployment of the CompuFlo® Epidural System at Advanced Spine and Pain Management marks a pivotal advancement in Milestone Scientific's market penetration strategy. The successful pilot program validation by Dr. Dhillon carries particular significance as it demonstrates real-world clinical adoption and validation of the technology's benefits in enhancing patient safety and procedural efficiency.
The Medicare price assignment is a game-changing development that addresses one of the primary barriers to adoption - reimbursement. This pricing structure makes the technology more accessible to healthcare providers and could accelerate market penetration. The integration into Advanced Spine and Pain Management, operating within the SurgiCore network of 12 centers in the NY/NJ metropolitan area, presents a strategic growth opportunity.
The market implications are substantial:
- The potential for systematic rollout across the entire SurgiCore network could serve as a blueprint for expansion into other regional medical networks
- Medicare price assignment typically influences private insurance coverage decisions, potentially creating a domino effect in reimbursement adoption
- The technology's ability to provide real-time feedback addresses a critical need in pain management procedures, where precision is paramount
The Dynamic Pressure Sensing Technology® represents a significant competitive advantage in the medical device space, particularly in pain management where procedure accuracy directly impacts patient outcomes and healthcare economics. The real-time feedback mechanism not only enhances safety but also potentially reduces procedure time and complications, creating a compelling value proposition for both providers and payers.
Reports Expanding Adoption of CompuFlo® Epidural System Following Previously Announced Medicare Price Assignment
ROSELAND, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, LLC, a premier pain management clinic. This rollout follows a successful pilot program conducted with Dr. Varinder Dhillon, whose expertise and feedback validate the clinical benefits of the CompuFlo® Epidural System in enhancing patient safety and procedural efficiency.
Advanced Spine and Pain Management operates out of SurgiCore Montvale, one of 12 SurgiCore centers located in the New York/New Jersey metropolitan area, highlighting the opportunity for further expansion within the SurgiCore network. In addition, the Company reports increasing adoption of the CompuFlo® Epidural System following the previously announced Medicare price assignment, reflecting its clinical and economic benefits.
The CompuFlo® Epidural System, utilizing Milestone Scientific’s patented Dynamic Pressure Sensing Technology®, provides real-time feedback to confirm accurate needle placement during epidural procedures. This innovative technology significantly reduces the risk of complications associated with traditional techniques, enhancing both patient safety and procedural efficiency.
Dr. Dhillon commented, "The CompuFlo® Epidural System has transformed the way we approach epidural procedures. The technology’s precision and reliability enable us to deliver safer and more comfortable care to our patients, while also improving procedural efficiency. I am thrilled integrate it into my workflow at Advanced Spine and Pain Management, and am confident it will continue to deliver outstanding results."
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "The adoption of the CompuFlo® Epidural System by Dr. Dhillon at Advanced Spine and Pain Management illustrates our traction within the healthcare community. With the recent Medicare price assignment, we are witnessing increased adoption of the CompuFlo Epidural System across pain management clinics and other healthcare facilities nationwide."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
What is the impact of Medicare price assignment on MLSS CompuFlo Epidural System adoption?
How many SurgiCore centers could potentially adopt MLSS CompuFlo system in the NY/NJ area?
What are the key benefits of MLSS CompuFlo Epidural System according to Dr. Dhillon?
How does MLSS CompuFlo Epidural System improve patient safety?
